Glaukos (GKOS) Expected to Announce Earnings on Thursday

Glaukos (NYSE:GKOS) is projected to post its quarterly earnings results after the market closes on Thursday, February 20th. Analysts expect Glaukos to post earnings of ($0.38) per share and revenue of $100.72 million for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Glaukos Stock Performance

Glaukos stock opened at $143.80 on Thursday. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. The company has a market cap of $7.93 billion, a P/E ratio of -47.62 and a beta of 1.04. Glaukos has a fifty-two week low of $83.90 and a fifty-two week high of $163.71. The firm’s 50 day simple moving average is $151.20 and its 200-day simple moving average is $137.79.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on GKOS shares. StockNews.com upgraded Glaukos from a “sell” rating to a “hold” rating in a research note on Monday, October 21st. BTIG Research boosted their price target on Glaukos from $140.00 to $149.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. Stifel Nicolaus raised their price objective on shares of Glaukos from $153.00 to $175.00 and gave the company a “buy” rating in a research report on Tuesday, December 31st. Stephens upgraded shares of Glaukos to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Wells Fargo & Company increased their price target on shares of Glaukos from $145.00 to $153.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. One analyst has rated the stock with a sell rating, two have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Glaukos has an average rating of “Moderate Buy” and an average price target of $151.08.

Insider Buying and Selling

In other Glaukos news, Director Gilbert H. Kliman sold 2,000 shares of the business’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $144.01, for a total transaction of $288,020.00. Following the sale, the director now directly owns 32,336 shares of the company’s stock, valued at $4,656,707.36. The trade was a 5.82 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, COO Joseph E. Gilliam sold 3,328 shares of the company’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $149.85, for a total value of $498,700.80. Following the sale, the chief operating officer now owns 102,169 shares in the company, valued at $15,310,024.65. The trade was a 3.15 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 15,328 shares of company stock valued at $2,289,521. 6.40% of the stock is owned by company insiders.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.